PassPort Technologies Reports Data from the P-I Study of Zolmitriptan Transdermal Microporation System to Treat Acute Migraine
Shots:
- Part A portion of the P-I trial evaluates the tolerability & PK of Zolmitriptan PassPort (microporation device + zolmitriptan patch) at 3 doses (0.75mg, 1.5mg & 3.0mg) vs zolmitriptan (2.5mg, oral)
- Plasma concentration of Zolmitriptan was detected within 2min. post Zolmitriptan PassPort administration vs 15min. post oral administration with a bioavailability of ~160% to 200%. The system was well-tolerated without any SAEs
- The ongoing Part B portion will evaluate the transdermal administration of a single dose of Zolmitriptan at other sites incl. the abdomen & upper thigh with final results anticipated in Q3’24. The company expects to out-license Zolmitriptan PassPort for further development and commercialization
Ref: PassPort Technologies | Image: PassPort Technologies
Related News:- Tonix Pharmaceuticals to Acquire Zembrace SymTouch and Tosymra from Upsher-Smith Laboratories for Acute Migraine
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
